Table 2 Analysis of overall survival

From: TEAD1 and c-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer

Variable

Group

N

d.f.

P -value

Hazard ratio

Lower 95% confidence interval

Upper 95% confidence interval

Univariate analysis

 c-Cbl staining intensity

1

32

1

 

1

  
 

2

44

1

0.1049

1.7123

0.8939

3.2802

 

3

25

1

0.0017

3.2627

1.5569

6.8375

 c-Cbl staining intensity

Continuous

101

1

0.0019

1.8090

1.2448

2.6290

 Age

Continuous

101

1

0.0002

1.0664

1.0304

1.1037

 PSA

Continuous

41

1

0.0009

1.0044

1.0018

1.0070

 Gleason score

Continuous

100

1

0.0000

1.3670

1.2048

1.5510

 Gleason score

Gleason<7

60

1

 

1

  
 

Gleason⩾7

40

1

0.0000

4.1135

2.3917

7.0748

 AJCC stage

1

2

1

0.2349

3.5565

0.4384

28.8493

 

2

36

1

 

1

  
 

3

24

1

0.0067

3.2883

1.3912

7.7726

 

4 M0

16

1

0.0005

4.7513

1.9644

11.4919

 

4 M1

23

1

0.0000

9.0662

3.9812

20.6460

Multivariate analysis

 c-Cbl staining intensity

Continuous

100

1

0.0005

1.9895

1.3513

2.9291

 Gleason score

Gleason<7

60

  

1

  
 

Gleason⩾7

40

1

0.0001

3.5851

1.9242

6.6795

 AJCC stage

1

2

1

0.1715

4.3962

0.5265

36.7064

 

2

36

  

1

  
 

3

23

1

0.4293

1.4602

0.5711

3.7333

 

4 M0

16

1

0.0039

3.7042

1.5206

9.0236

 

4 M1

23

1

0.0000

8.6743

3.6294

20.7316

 Variables not in the model

       

 Age

Continuous

100

1

0.3219

   

Univariate analysis

 TEAD1 staining intensity

0

7

1

 

1

  
 

1

30

1

0.2966

1.9435

0.5580

6.7693

 

2

49

1

0.1981

2.1990

0.6624

7.3009

 

3

10

1

0.0033

7.4536

1.9482

28.5157

 TEAD1 staining intensity

Continuous

96

1

0.0065

1.7102

1.1621

2.5169

 Age

Continuous

96

1

0.0004

1.0673

1.0293

1.1066

 PSA

Continuous

38

1

0.0045

1.0048

1.0015

1.0081

 Gleason score

Continuous

94

1

0.0000

1.3415

1.1784

1.5272

 Gleason score

Gleason<7

57

1

 

1

  
 

Gleason⩾7

37

1

0.0000

4.2115

2.3747

7.4688

 AJCC stage

1

2

1

0.1672

4.4911

0.5331

37.8367

 

2

34

1

 

1

  
 

3

24

1

0.0022

4.4203

1.7105

11.4227

 

4 M0

16

1

0.0005

5.7426

2.1493

15.3436

 

4 M1

20

1

0.0000

12.0225

4.7692

30.3073

Multivariate analysis

 TEAD1 staining intensity

Continuous

94

1

0.0365

1.5615

1.0284

2.3708

 Gleason score

Gleason<7

57

1

 

1

  
 

Gleason⩾7

37

1

0.0011

3.0741

1.5632

6.0455

 AJCC stage

1

2

1

0.0536

8.5127

0.9677

74.8866

 

2

34

1

 

1

  
 

3

23

1

0.0840

2.4744

0.8855

6.9144

 

4 M0

16

1

0.0035

4.4048

1.6275

11.9214

 

4 M1

19

1

0.0000

12.6098

4.7733

33.3118

 Variables not in the model

       

 Age

Continuous

94

1

0.0646

   
  1. PSA=prostate-specific antigen.
  2. Statistical tests were performed as described in Materials and Methods. For statistical analysis, the AJCC stage 4 tumours were divided into categories without (M0) or with (M1) distant metastases.
Back to article page